C07K 16/104
Severe acute respiratory syndrome coronavirus 2 [sars‐cov‐2]
Official title: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
C07K16/104 (Severe acute respiratory syndrome coronavirus 2 [sars‐cov‐2]) appears on 140 US grants and 679 published applications in this corpus.
Search patents in C07K- Granted patents
- 140
- Published applications
- 679
- Assignees
- 439
- Inventors
- 2,163
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 0 | 1 |
| 2016 | 0 | 3 |
| 2017 | 0 | 3 |
| 2018 | 0 | 5 |
| 2019 | 5 | 3 |
| 2020 | 4 | 7 |
| 2021 | 15 | 52 |
| 2022 | 20 | 71 |
| 2023 | 19 | 179 |
| 2024 | 29 | 178 |
| 2025 | 25 | 117 |
| 2026 | 23 | 58 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Use of SARS-CoV-2 receptor binding motif (RBM)-reactive monoclonal antibodies to treat COVID-196 Oct 2026US 12,753,417 B2The Feinstein Institutes for Medical Research
- Binding protein specific for the spike protein of severe acute respiratory syndrome corona virus 2 (SARS-CoV-2)6 Oct 2026US 12,754,184 B2Navigo Proteins GmbH
- Follicular helper T (TFH) cells specific to SARS-COV-2 virus15 Sep 2026US 12,734,232 B2The University of Osaka
- Methods of identifying subjects having an increased risk of developing a coronavirus infection and treatment thereof15 Sep 2026US 12,735,752 B2Regeneron Pharmaceuticals, Inc.
- Compositions and methods for the detection and treatment of SARS-CoV-2 virus infection1 Sep 2026US 12,724,030 B2Georgia Tech Research Corporation
- Humoral modulation in vaccinated and virally infected subjects with granulocyte-macrophage colony-stimulating factor (gm-csf)1 Oct 2026US 2026/0295009 A1Partner Therapeutics, Inc.
- Intranasal Administration of a Polyclonal Blood Derivative Directed Against a Pathogen Agent for the Prevention and/or Treatment of an Airborne Disease24 Sep 2026US 2026/0285951 A1Prevor International
- Antibodies that bind to multiple sarbecoviruses17 Sep 2026US 2026/0274928 A1Vir Biotechnology, Inc.
- Sars-cov2 antibodies and methods of use thereof10 Sep 2026US 2026/0265350 A1Invivyd, Inc.
- Sars-cov-2 antibodies and bispecific antibodies27 Aug 2026US 2026/0250363 A1AP Biosciences, Inc.
Most cited
By later US patents
- Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments41US 10,787,501 B1Regeneron Pharmaceuticals, Inc. · 2020
- Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments21US 10,954,289 B1Regeneren Pharmaceuticals, Inc. · 2021
- Molecules that bind to SARS-CoV-214US 10,822,379 B1University of Pittsburgh—Of the Commonwealth System of Higher Education · 2020
- Anti-SARS-Cov-2 antibodies derived from 2GHW10US 11,021,531 B1Centivax, Inc. · 2021
- Anti-SARS-Cov-2 antibodies derived from 3bgf10US 11,028,167 B1Centivax, Inc. · 2021